How Does Relfydess™ vs Botox®, Bocouture®, Xeomin®, Dysport®, Alluzience® and Azzalure® An Advanced Clinical and Pharmacological Analysis

A Next Generation Botulinum Toxin in the UK Aesthetic Landscape with Relfydess, Botox and Xeomin.

An Integrated Clinical, Pharmacological and Regulatory Review of Relfydess, Botox, Xeomin, Bocouture, Dysport, Alluzience and Azzalure

Botulinum toxin type A remains the foundation of aesthetic neuromodulation in the UK. What has changed is not the mechanism, but the expectation. Patients now prioritise rapid visible onset, extended duration, predictable diffusion, low immunogenic potential, procedural consistency and long‑term value.

This unified document combines detailed individual monographs with structured cross‑comparison, pharmacokinetic analysis, diffusion modelling, resistance strategy, regulatory context and economic evaluation. It is written for advanced injectors, governance leads and clinicians seeking depth rather than marketing rhetoric.

Read on for the full in-depth write up or for our quick guide clinic on the link below

Haus Of Ästhetik - Comprehensive Botulinum Toxin Type A Comparison.pdf

Download PDF • 504KB

Evidence Grading Framework

Grade A – High quality randomised controlled trials or long term registry data

Grade B – Prospective cohort or well designed observational data

Grade C – Mechanistic modelling, laboratory or expert consensus

Grade D – Emerging data or manufacturer supplied evidence

Core Mechanism of Action (Applies to All Products)

All botulinum toxin type A formulations act by:

• Binding to presynaptic cholinergic nerve terminals

• Internalisation via endocytosis

• Cleavage of SNAP‑25 within the SNARE complex

• Inhibition of acetylcholine vesicle fusion

• Temporary chemical denervation of the target muscle

Differences between products relate to formulation, stabilisation, complexing proteins, diffusion behaviour and duration of synaptic inhibition rather than the fundamental mechanism itself.

INDIVIDUAL PRODUCT MONOGRAPHS

Relfydess (Liquid Botulinum Toxin Type A)

Molecular Profile

• 150 kDa purified neurotoxin

• No accessory complexing proteins

• Albumin free

• Proprietary stabilisation technology

• Ready to inject liquid

• Cold chain 2–8°C

Onset

Approximately 39 percent visible improvement within 24 hours in Phase III READY data. Majority respond by Day 3.

Evidence Grade: B–D

Duration

Up to 6 months maintained correction reported in trial populations.

Evidence Grade: B–D

Diffusion

Designed for controlled spread. Independent modelling data limited.

Strengths

Rapid onset. Extended plateau phase. Reduced antigenic exposure. No reconstitution variability.

Limitations

Limited long term registry data. Higher acquisition cost. Emerging UK data.

Botox (OnabotulinumtoxinA)

Molecular Profile

• 150 kDa neurotoxin within approximately 900 kDa protein complex

• Contains human serum albumin

• Lyophilised powder

• Cold chain required

Reconstitution

Preservative free 0.9 percent sodium chloride. Typical UK dilution 2.5 mL per 100 units.

Onset

Day 3–5 typical.

Evidence Grade: A

Duration

3–4 months consistent across aesthetic indications.

Evidence Grade: A

Diffusion

Approximately 1–1.5 cm radius depending on dilution and injection depth.

Evidence Grade: C

Strengths

Most extensive global safety data. Broad neurological licensing. High reproducibility.

Limitations

Standard duration. Reconstitution required. Contains accessory proteins and albumin.

Xeomin (IncobotulinumtoxinA)

Molecular Profile

• 150 kDa purified neurotoxin

• No accessory proteins

• Albumin stabiliser present

• Ambient storage below 25°C pre reconstitution

Onset

Day 3–5.

Evidence Grade: A–B

Duration

3–4 months.

Evidence Grade: A–B

Diffusion

Controlled spread similar to onabotulinum.

Evidence Grade: C

Strengths

Reduced total protein load. Suitable for long term repeat patients. Ambient storage advantage.

Limitations

Standard duration. Reconstitution variability possible.

Bocouture (IncobotulinumtoxinA)

Molecular Profile

• Identical active neurotoxin to Xeomin

• No complexing proteins

• Ambient storage below 25°C

• Powder formulation

Onset

2–4 days typical.

Evidence Grade: A–B

Duration

3–4 months.

Evidence Grade: A–B

Strengths

Low theoretical immunogenic burden. Simplified stock management. Predictable performance.

Limitations

Requires reconstitution. Standard duration profile.

Dysport (AbobotulinumtoxinA)

Molecular Profile

• 150 kDa neurotoxin within 500–900 kDa complex

• Contains accessory proteins and albumin

• Cold chain required

Onset

Often 2–3 days, especially in larger muscle groups.

Evidence Grade: A–B

Duration

3–5 months depending on dose and muscle bulk.

Evidence Grade: A–B

Diffusion

Broader field spread approximately 1.5–2 cm.

Evidence Grade: C

Strengths

Effective in larger muscles such as masseter. Strong neurological heritage.

Limitations

Higher protein load. Unit conversion complexity. Reconstitution required.

Azzalure (AbobotulinumtoxinA)

Molecular Profile

• Aesthetic presentation of abobotulinumtoxinA

• Protein complex 500–900 kDa

• Cold chain required

Onset

2–3 days typical.

Evidence Grade: B

Duration

3–4 months average.

Evidence Grade: B

Diffusion

Moderately broader spread profile.

Evidence Grade: C

Strengths

Effective dynamic line correction. Familiar aesthetic dosing.

Limitations

Higher antigenic exposure than incobotulinum formulations. Reconstitution required.

Alluzience (Liquid AbobotulinumtoxinA)

Molecular Profile

• Liquid abobotulinumtoxinA

• Accessory proteins and albumin present

• Ready to inject

• Cold chain required

Onset

Day 1–3 in controlled trials.

Evidence Grade: B

Duration

4–6 months in many patients.

Evidence Grade: B

Diffusion

Similar broader spread to Dysport lineage.

Evidence Grade: C

Strengths

Eliminates dilution error. Faster onset than most powders.

Limitations

Albumin exposure. Cold chain dependency. Less long term registry data than Botox.

CROSS PRODUCT ANALYSIS

Pharmacokinetic and Structural Comparison

Product	Active Size	Complex Size	Accessory Proteins	Albumin	Typical Duration	Evidence
Relfydess	150 kDa	150 kDa	None	No	Up to 6 months	B–D
Botox	150 kDa	~900 kDa	Yes	Yes	3–4 months	A
Xeomin	150 kDa	150 kDa	None	Yes	3–4 months	A–B
Bocouture	150 kDa	150 kDa	None	Yes	3–4 months	A–B
Dysport	150 kDa	500–900 kDa	Yes	Yes	3–5 months	A–B
Azzalure	150 kDa	500–900 kDa	Yes	Yes	3–4 months	B
Alluzience	150 kDa	500–900 kDa	Yes	Yes	4–6 months	B

Diffusion Modelling Summary

Onabotulinum and incobotulinum: approximately 1–1.5 cm radius

Abobotulinum lineage: approximately 1.5–2 cm radius

Evidence Grade: C

Clinical interpretation: broader spread may benefit large muscle groups but requires precision in periocular work.

Duration Curve Explanation for Patients

Traditional toxins follow three phases:

1. Early rise phase over 3–5 days

2. Plateau phase lasting approximately 8–10 weeks

3. Gradual return of movement by months 3–4

Extended duration products demonstrate:

1. Faster rise

2. Prolonged plateau

3. Later neuromuscular recovery

Imagine two curves. One peaks and descends steadily. The other peaks faster and holds the top longer before descending.

Resistance and Long Term Management

True neutralising antibody formation is rare in aesthetic dosing. Risk increases with high cumulative dose and frequent retreatment.

Strategy:

• Maintain minimum 12 week interval

• Avoid unnecessary dose escalation

• Consider lower protein load products in suspected secondary non response

• Confirm injection technique before diagnosing resistance

Evidence Grade: B–C

Injector Selection Algorithm by Phenotype

Rapid event driven result → Relfydess or Alluzience

Long term maintenance user → Xeomin or Bocouture

High muscle bulk → Dysport or Azzalure

Brand reassurance priority → Botox

Fewer annual visits desired → Relfydess

UK Regulatory Context

All products are prescription only medicines regulated by the MHRA. Prescribing must comply with UK medicines legislation, CQC Regulation 12 and 17, and professional prescribing standards.

Botox, Dysport and Xeomin possess broad neurological indications. Bocouture, Azzalure and Alluzience are primarily aesthetic licensed. Relfydess follows European approval pathways with UK regulatory alignment.

Economic Evaluation

Monthly Cost of Effect = Vial Cost ÷ Average Duration (months)

Longer duration products may provide superior annual value despite higher initial cost.

Final Perspective

Relfydess introduces meaningful innovation in onset speed and duration. Botox remains the benchmark for evidence depth. Xeomin and Bocouture offer reduced protein load advantages. Dysport and Azzalure provide broader diffusion for selected indications. Alluzience offers liquid convenience with moderate extension of duration.

Clinical excellence lies not in product loyalty but in anatomical precision, pharmacological understanding, resistance awareness and regulatory compliance.

At Haus of Ästhetik, neuromodulator selection remains patient specific, evidence led and outcome focused.

Extended Reference

1. Carruthers J, Carruthers A. Advances in botulinum toxin type A formulations. Dermatologic Surgery. 2015;41(S1):S15–S23.

2. Flynn TC. Botulinum toxin: Overview and clinical implications. Dermatologic Clinics. 2010;28(1):1–9.

3. Hexsel D, et al. Comparative review of botulinum toxin formulations. Journal of Clinical and Aesthetic Dermatology. 2019;12(5):30–36.

4. Satriyasa BK. Botulinum toxin A for facial wrinkles: A literature review. Clinical, Cosmetic and Investigational Dermatology. 2019;12:223–228.

5. Dressler D, Saberi FA. Botulinum toxin: Mechanisms of action. European Neurology. 2005;53(1):3–9.

6. Dressler D, Bigalke H. Immunological aspects of botulinum toxin therapy. Journal of Neural Transmission. 2018;125(4):603–609.

7. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26(2):e1–e9.

8. European Medicines Agency. Summary of Product Characteristics for onabotulinumtoxinA, incobotulinumtoxinA and abobotulinumtoxinA formulations.

9. Medicines and Healthcare products Regulatory Agency. Guidance on prescription only medicines and safe prescribing practice in the UK.

10. READY Phase III Clinical Programme Data. Renaissance Pharma GmbH. Product monograph and clinical trial summaries.

11. Lowe NJ, et al. Duration of botulinum toxin type A in aesthetic practice. Aesthetic Surgery Journal. 2018;38(S1):S7–S15.

12. Kane MA, et al. Onset and duration characteristics of botulinum toxin type A formulations. Dermatologic Surgery. 2010;36(Suppl 4):1719–1728.

13. Jankovic J, et al. Long term efficacy and safety of botulinum toxin in clinical practice. Movement Disorders. 2004;19(Suppl 8):S38–S45.

14. International Society of Aesthetic Plastic Surgery. Global survey on aesthetic neuromodulator trends. 2022.

15. Pickett A, Perrow K. Diffusion characteristics of botulinum toxin type A formulations. Toxins. 2011;3(9):1185–1204.

16. Kerscher M, et al. Comparative evaluation of ready to use liquid botulinum toxin formulations. Journal of Cosmetic Dermatology. 2021;20(7):2104–2112.

17. Brin MF, et al. Safety and tolerability of repeated botulinum toxin administration. Neurology. 2008;70(5):359–367.

18. Cox SE, et al. Clinical considerations in neuromodulator selection. Aesthetic Surgery Journal. 2020;40(6):NP281–NP292.

19. UK Care Quality Commission. Regulation 12 and 17 guidance on medicines management and governance.

20. British Association of Aesthetic Plastic Surgeons. Guidance on safe aesthetic practice and neuromodulator administration.